A new trading day began on Tuesday, with Day One Biopharmaceuticals Inc (NASDAQ: DAWN) stock price up 3.45% from the previous day of trading, before settling in for the closing price of $12.77. DAWN’s price has ranged from $11.13 to $18.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 68.74%. With a float of $72.64 million, this company’s outstanding shares have now reached $100.81 million.
In an organization with 155 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.37%, operating margin of -206.27%, and the pretax margin is -81.57%.
Day One Biopharmaceuticals Inc (DAWN) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Day One Biopharmaceuticals Inc is 27.97%, while institutional ownership is 81.41%. The most recent insider transaction that took place on Dec 10 ’24, was worth 399,339. In this transaction HEAD OF R&D of this company sold 30,000 shares at a rate of $13.31, taking the stock ownership to the 1,034,015 shares. Before that another transaction happened on Nov 18 ’24, when Company’s CHIEF EXECUTIVE OFFICER sold 10,554 for $13.21, making the entire transaction worth $139,420. This insider now owns 108,377 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.74% per share during the next fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Here are Day One Biopharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 14.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.01, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -1.16 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Let’s dig in a bit further. During the last 5-days, its volume was 0.92 million. That was inferior than the volume of 1.18 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 82.10%. Additionally, its Average True Range was 0.56.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 36.94%, which indicates a significant decrease from 86.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.72% in the past 14 days, which was higher than the 38.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.93, while its 200-day Moving Average is $14.08. However, in the short run, Day One Biopharmaceuticals Inc’s stock first resistance to watch stands at $13.64. Second resistance stands at $14.07. The third major resistance level sits at $14.60. If the price goes on to break the first support level at $12.67, it is likely to go to the next support level at $12.14. The third support level lies at $11.71 if the price breaches the second support level.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
With a market capitalization of 1.33 billion, the company has a total of 100,846K Shares Outstanding. Currently, annual sales are 0 K while annual income is -188,920 K. The company’s previous quarter sales were 93,760 K while its latest quarter income was 37,040 K.
